Oslo Cancer Cluster is the most mature biomedical innovation cluster in Norway.The cluster is well positioned in the global oncology industry, and has developed the Nordics as an international hub for oncology innovation. Since 2007 we have built a broad base of international partnerships, and the cluster attracts foreign capital. We have a proven track-record for international success in commercialization of health research: Photocure successfully launched 2 new products on the market in only 5 years. Algeta launched Xofigo in 2013 and is now expanding greatly in Norway as part of Bayer AG. We currently hold a world-class pipeline in particularly potent fields of cancer research and will open Oslo Cancer Cluster Innovation Park and Incubator, a unique and internationally attractive space for research and industry development, in Oslo in August 2015.
At present Oslo Cancer Cluster has around 70 members from Norway, the Nordic region and Europe. This includes global biopharmaceutical companies, academic institutions, biotech companies and companies with supporting functions. Most of the biotech companies are spin-offs from academic cancer research.